Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeneca B Regulatory News (SVCT)

Share Price Information for Seneca B (SVCT)

Share Price is delayed by 15 minutes
Get Live Data
44.00    0.00 (0.00%)
Bid:
43.00
Ask:
45.00
Spread: 2.00 (4.651%)
Market Cap: £14.56m
SVCT Live PriceLast checked at - London Stock Exchange

Intraday Seneca B Share Chart

Updated NAV & Ordinary Share Class Dividend

15 Oct 2025 16:26

RNS Number : 5441D
Seneca Growth Capital VCT PLC
15 October 2025
 

Updated Net Asset Values and Ordinary Share Class Dividend Declaration

Seneca Growth Capital VCT Plc 

15 October 2025

 

Seneca Growth Capital VCT Plc

Unaudited Net Asset Value ("NAV") Update as at 30 September 2025

The Directors of Seneca Growth Capital VCT Plc (the "Company") and the Investment Manager of the Company, Seneca Partners Limited ("Seneca"), have reviewed the valuation of the Company's investment portfolios for the quarter ending 30 September 2025 and announce an updated NAV for each of the Company's Ordinary and B share classes as at 30 September 2025.

For the purposes of calculating the NAV per share for both share classes, quoted investments are valued in line with closing bid prices as at 30 September 2025 and unquoted investments are carried at fair value.

B share NAV as at 30 September 2025

As at 30 September 2025, the unaudited B share NAV was 47.7p per share, a 2% decrease from the previously published unaudited NAV as at 30 June 2025 of 48.7p.

The B share NAV Total Return was 67.2p compared to 68.2p as at 30 June 2025.

The 1.0p decrease in NAV per B share in the quarter is principally due to movements in the share prices of the B share pool's AIM/AQSE quoted investee companies during the quarter.

Ordinary share NAV as at 30 September 2025

As at 30 September 2025, the unaudited Ordinary share NAV was 13.1p per share, a 16% increase from the previously published unaudited NAV as at 30 June 2025 of 11.3p.

The Ordinary share NAV Total Return was 89.4p compared to 87.6p as at 30 June 2025.

The 1.8p increase in NAV per Ordinary share is principally due to the increase in the share price of AIM quoted Arecor Therapeutics Plc ("Arecor") and Scancell Holdings Plc ("Scancell").

Scancell was the largest holding in the Ordinary share portfolio, representing 92% of the Ordinary share NAV as at 30 June 2025. As a result, the Ordinary share NAV moved largely in line with the movement in the Scancell share price during the quarter. The Company was presented with an opportunity to de-risk the concentration of the holding for Ordinary shareholders and was able to achieve a profitable exit of c.47% of the Ordinary share pool's holding as at 30 June 2025. Seneca was able to realise £435k in proceeds from the disposal, which generated a profit of £172k, resulting in an average weighted return of 1.7x on original investment cost. This disposal has enabled the Company to declare a second interim capital dividend of 5.0p per Ordinary share.

The Ordinary share pool's unquoted investments have all previously been written down to £nil carrying value. The valuations of the Ordinary share pool's unquoted investments remain unchanged as at the quarter end.

Second Interim Capital Dividend on Ordinary Shares

The Directors of the Company are pleased to declare an interim capital dividend of 5.0 pence per Ordinary Share for the year to 31 December 2025, to be paid on 7 November 2025.

The ex-dividend date is 23 October 2025.

The record date for the dividend is 24 October 2025.

The dividend payment date is 7 November 2025.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this information is now considered to be in the public domain.

For further information, please contact:

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk

Siobhan Pycroft, Seneca Partners Limited at Siobhan.Pycroft@senecapartners.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVPKPBBPBDDBKD
Date   Source Headline
4th Jun 20261:34 pmRNSResults of Annual General Meeting voting
30th Apr 202612:12 pmRNSAnnual Report, Notice of AGM and new NAVs
20th Mar 20264:36 pmRNSUnaudited Net asset value (“NAV”) Update
28th Nov 202512:06 pmRNSShare Buy-back and Total Voting Rights
11th Nov 202512:11 pmRNSSecond Interim Dividend on B Shares
21st Oct 20252:40 pmRNSPDMR Shareholding
15th Oct 20254:26 pmRNSUpdated NAV & Ordinary Share Class Dividend
26th Sep 20251:50 pmRNSUnaudited Half-year Report for 6m to 30 June 2025
8th Aug 20254:05 pmRNSIssue of Equity and Total Voting Rights
2nd Jun 20253:15 pmRNSShare Buy-back and Total Voting Rights
22nd May 20251:20 pmRNSResult of AGM
12th May 20254:02 pmRNSInterim Capital Dividend on Ordinary Shares
7th May 20253:04 pmRNSIssue of Equity and Total Voting Rights
29th Apr 20253:58 pmRNSIssue of Supplementary Prospectus
23rd Apr 20254:15 pmRNSFinal results and Notice of AGM
4th Apr 20253:37 pmRNSIssue of Equity and Total Voting Rights
3rd Apr 20257:00 amRNSNet Asset Value(s)
19th Mar 20257:00 amRNSInterim Dividend on B Shares
11th Dec 20242:44 pmRNSDirector/PDMR Dealing
11th Dec 20242:39 pmRNSIssue of Equity and Total Voting Rights
15th Nov 20243:15 pmRNSShare Buy-back and Total Voting Rights
14th Nov 20243:32 pmRNSSecond Interim Dividend on B Shares
16th Oct 20247:00 amRNSNet Asset Value(s)
12th Sep 20242:11 pmRNSOffer for Subscription and Prospectus Publication
9th Aug 20243:20 pmGNWIssue of Equity and Total Voting Rights
6th Aug 202410:10 amGNWClosure of Offer for Subscription
25th Jul 20247:00 amGNWHalf-year Report
15th May 202412:16 pmGNWResult of AGM
1st May 20243:34 pmGNWIssue of Equity and Total Voting Rights
1st May 20247:00 amGNWB Share Net Asset Value
22nd Apr 202410:46 amGNWShare Buy-back and Total Voting Rights
5th Apr 202412:44 pmGNWIssue of Equity and Total Voting Rights
4th Apr 20247:00 amGNWNet Asset Value(s)
28th Mar 202412:11 pmGNWIssue of Supplementary Prospectus
22nd Mar 20247:00 amGNWFinal Results, Notice of AGM, Updated NAV
7th Mar 20247:00 amGNWInterim Dividend on B Shares
19th Feb 20244:36 pmGNWDirector Declaration
21st Dec 202312:03 pmGNWIssue of Equity and Total Voting Rights
6th Dec 20233:24 pmGNWDirector/PDMR Dealing
6th Dec 20233:14 pmGNWIssue of Equity and Total Voting Rights
29th Nov 202312:36 pmGNWChange of the Company’s Auditor
20th Nov 20233:20 pmGNWB Share Buy-back and Total Voting Rights
3rd Nov 20237:00 amGNWDividend Declaration
12th Oct 20237:00 amGNWNet Asset Value(s)
11th Oct 20233:39 pmGNWDirectorate Change
24th Aug 20234:18 pmGNWOffer for Subscription and Publication of Prospectus
18th Aug 20235:08 pmGNWIssue of Equity and Total Voting Rights and Capital Reorganisation
2nd Aug 202311:40 amGNWHalf-year Report
30th Jun 20231:58 pmGNWIssue of Equity and Total Voting Rights
20th Jun 20238:50 amGNWShare Buy-back and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.